Publication: Benign and tumor parenchyma metabolomic profiles affect compensatory renal growth in renal cell carcinoma surgical patients
Open/View Files
Date
2017
Published Version
Journal Title
Journal ISSN
Volume Title
Publisher
Public Library of Science
The Harvard community has made this article openly available. Please share how this access benefits you.
Citation
Rosenzweig, B., N. D. Rubinstein, E. Reznik, R. Shingarev, K. Juluru, O. Akin, J. J. Hsieh, et al. 2017. “Benign and tumor parenchyma metabolomic profiles affect compensatory renal growth in renal cell carcinoma surgical patients.” PLoS ONE 12 (7): e0180350. doi:10.1371/journal.pone.0180350. http://dx.doi.org/10.1371/journal.pone.0180350.
Research Data
Abstract
Background and objectives Pre-operative kidney volume is an independent predictor of glomerular filtration rate in renal cell carcinoma patients. Compensatory renal growth (CRG) can ensue prior to nephrectomy in parallel to tumor growth and benign parenchyma loss. We aimed to test whether renal metabolite abundances significantly associate with CRG, suggesting a causative relationship. Design, setting, participants, and measurements Tissue metabolomics data from 49 patients, with a median age of 60 years, were previously collected and the pre-operative fold-change of their contra to ipsi-lateral benign kidney volume served as a surrogate for their CRG. Contra-lateral kidney volume fold-change within a 3.3 +/- 2.1 years follow-up interval was used as a surrogate for long-term CRG. Using a multivariable statistical model, we identified metabolites whose abundances significantly associate with CRG. Results: Our analysis found 13 metabolites in the benign (e.g. L-urobilin, Variable Influence in Projection, VIP, score = 3.02, adjusted p = 0.017) and 163 metabolites in the malignant (e.g. 3-indoxyl-sulfate, VIP score = 1.3, adjusted p = 0.044) tissues that significantly associate with CRG. Benign/tumor fold change in metabolite abundances revealed three additional metabolites with that significantly positively associate with CRG (e.g. p-cresol sulfate, VIP score = 2.945, adjusted p = 0.033). At the pathway level, we show that fatty-acid oxidation is highly enriched with metabolites whose benign tissue abundances strongly positively associate with CRG, both pre-operatively and long term, whereas in the tumor tissue significant enrichment of dipeptides and benzoate (positive association), glycolysis/gluconeogenesis, lysolipid and nucleotide sugar pentose (negative associations) sub-pathways, were observed. Conclusion: These data suggest that specific biological processes in the benign as well as in the tumor parenchyma strongly influence compensatory renal growth.
Description
Other Available Sources
Keywords
Biology and Life Sciences, Biochemistry, Metabolism, Metabolites, Anatomy, Renal System, Kidneys, Medicine and Health Sciences, Oncology, Cancers and Neoplasms, Benign Tumors, Metabolomics, Physical Sciences, Chemistry, Chemical Compounds, Salts, Sulfates, Cell Biology, Cellular Structures and Organelles, Cell Membranes, Membrane Metabolism, Surgical and Invasive Medical Procedures, Surgical Excision, Nephrectomy, Radical Nephrectomy, Urinary System Procedures
Terms of Use
This article is made available under the terms and conditions applicable to Other Posted Material (LAA), as set forth at Terms of Service